Cargando…
Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
We have reported that the plasma zinc concentration gradually decreases with the progression of fibrosis and is related to hepatocellular carcinoma (HCC) development. The aim of this study was to examine the impact of the zinc concentration on HCC development (study 1) and the relationship between z...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631098/ https://www.ncbi.nlm.nih.gov/pubmed/34752016 http://dx.doi.org/10.1002/hep4.1782 |
_version_ | 1784607484445458432 |
---|---|
author | Hosui, Atsushi Tanimoto, Takashi Okahara, Toru Ashida, Munehiro Ohnishi, Kohsaku Wakahara, Yuhei Kusumoto, Yukihiro Yamaguchi, Toshio Sueyoshi, Yuka Hirao, Motohiro Yamada, Takuya Hiramatsu, Naoki |
author_facet | Hosui, Atsushi Tanimoto, Takashi Okahara, Toru Ashida, Munehiro Ohnishi, Kohsaku Wakahara, Yuhei Kusumoto, Yukihiro Yamaguchi, Toshio Sueyoshi, Yuka Hirao, Motohiro Yamada, Takuya Hiramatsu, Naoki |
author_sort | Hosui, Atsushi |
collection | PubMed |
description | We have reported that the plasma zinc concentration gradually decreases with the progression of fibrosis and is related to hepatocellular carcinoma (HCC) development. The aim of this study was to examine the impact of the zinc concentration on HCC development (study 1) and the relationship between zinc intake and HCC development (study 2) in patients with hepatitis C virus (HCV) eradicated by direct‐acting antivirals (DAAs). A total of 599 sustained virological response (SVR) patients treated with DAAs without a history of HCC were retrospectively analyzed in this study. Eighty patients received supplemental zinc (Zn treatment group), and 519 patients did not receive zinc (no Zn treatment group). In study 1, the cumulative incidence rate of HCC was compared between the Zn treatment group and the no Zn treatment group. In study 2, the risk factors for HCC development were examined in the no Zn treatment group. In study 1, in the Zn treatment group, HCC did not develop during follow‐up, and the cumulative risk of HCC was significantly lower in the Zn treatment group than in the no Zn treatment group (P = 0.048). In study 2, the 1‐year and 3‐year cumulative incidence rates of HCC were 1.8% and 5.6%, respectively. The risk factors for HCC identified by multivariate analysis were male sex, cirrhosis, low platelet count before treatment, and low serum zinc concentration 12 weeks after the end of DAA therapy. Conclusion: The Zn concentration is related to HCC development in patients with HCV eradicated by DAA therapy. Oral zinc supplementation is recommended as a means of suppressing HCC development in patients who have achieved SVR. |
format | Online Article Text |
id | pubmed-8631098 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86310982021-12-06 Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA Hosui, Atsushi Tanimoto, Takashi Okahara, Toru Ashida, Munehiro Ohnishi, Kohsaku Wakahara, Yuhei Kusumoto, Yukihiro Yamaguchi, Toshio Sueyoshi, Yuka Hirao, Motohiro Yamada, Takuya Hiramatsu, Naoki Hepatol Commun Original Articles We have reported that the plasma zinc concentration gradually decreases with the progression of fibrosis and is related to hepatocellular carcinoma (HCC) development. The aim of this study was to examine the impact of the zinc concentration on HCC development (study 1) and the relationship between zinc intake and HCC development (study 2) in patients with hepatitis C virus (HCV) eradicated by direct‐acting antivirals (DAAs). A total of 599 sustained virological response (SVR) patients treated with DAAs without a history of HCC were retrospectively analyzed in this study. Eighty patients received supplemental zinc (Zn treatment group), and 519 patients did not receive zinc (no Zn treatment group). In study 1, the cumulative incidence rate of HCC was compared between the Zn treatment group and the no Zn treatment group. In study 2, the risk factors for HCC development were examined in the no Zn treatment group. In study 1, in the Zn treatment group, HCC did not develop during follow‐up, and the cumulative risk of HCC was significantly lower in the Zn treatment group than in the no Zn treatment group (P = 0.048). In study 2, the 1‐year and 3‐year cumulative incidence rates of HCC were 1.8% and 5.6%, respectively. The risk factors for HCC identified by multivariate analysis were male sex, cirrhosis, low platelet count before treatment, and low serum zinc concentration 12 weeks after the end of DAA therapy. Conclusion: The Zn concentration is related to HCC development in patients with HCV eradicated by DAA therapy. Oral zinc supplementation is recommended as a means of suppressing HCC development in patients who have achieved SVR. John Wiley and Sons Inc. 2021-08-03 /pmc/articles/PMC8631098/ /pubmed/34752016 http://dx.doi.org/10.1002/hep4.1782 Text en © 2021 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Hosui, Atsushi Tanimoto, Takashi Okahara, Toru Ashida, Munehiro Ohnishi, Kohsaku Wakahara, Yuhei Kusumoto, Yukihiro Yamaguchi, Toshio Sueyoshi, Yuka Hirao, Motohiro Yamada, Takuya Hiramatsu, Naoki Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA |
title | Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
|
title_full | Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
|
title_fullStr | Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
|
title_full_unstemmed | Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
|
title_short | Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
|
title_sort | oral zinc supplementation decreases the risk of hcc development in patients with hcv eradicated by daa |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631098/ https://www.ncbi.nlm.nih.gov/pubmed/34752016 http://dx.doi.org/10.1002/hep4.1782 |
work_keys_str_mv | AT hosuiatsushi oralzincsupplementationdecreasestheriskofhccdevelopmentinpatientswithhcveradicatedbydaa AT tanimototakashi oralzincsupplementationdecreasestheriskofhccdevelopmentinpatientswithhcveradicatedbydaa AT okaharatoru oralzincsupplementationdecreasestheriskofhccdevelopmentinpatientswithhcveradicatedbydaa AT ashidamunehiro oralzincsupplementationdecreasestheriskofhccdevelopmentinpatientswithhcveradicatedbydaa AT ohnishikohsaku oralzincsupplementationdecreasestheriskofhccdevelopmentinpatientswithhcveradicatedbydaa AT wakaharayuhei oralzincsupplementationdecreasestheriskofhccdevelopmentinpatientswithhcveradicatedbydaa AT kusumotoyukihiro oralzincsupplementationdecreasestheriskofhccdevelopmentinpatientswithhcveradicatedbydaa AT yamaguchitoshio oralzincsupplementationdecreasestheriskofhccdevelopmentinpatientswithhcveradicatedbydaa AT sueyoshiyuka oralzincsupplementationdecreasestheriskofhccdevelopmentinpatientswithhcveradicatedbydaa AT hiraomotohiro oralzincsupplementationdecreasestheriskofhccdevelopmentinpatientswithhcveradicatedbydaa AT yamadatakuya oralzincsupplementationdecreasestheriskofhccdevelopmentinpatientswithhcveradicatedbydaa AT hiramatsunaoki oralzincsupplementationdecreasestheriskofhccdevelopmentinpatientswithhcveradicatedbydaa |